Analytical Data
-
Gene name
PTGS2
- Application
-
Alternative Names
Cyclooxygenase-2 ;COX-2;PHS IIProstaglandin H2 synthase 2 ;PGH synthase 2 ;PGHS-2;Prostaglandin-endoperoxide synthase 2
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P35354
-
Expression Region
18-601aa
-
Molecular Weight
70.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTGS2, also known as cyclooxygenase-2 (COX-2), is an enzyme that plays a critical role in the inflammatory response and is involved in the conversion of arachidonic acid into prostaglandins, which are key mediators of inflammation. The overexpression of PTGS2 is associated with various pathological conditions, including cancer, cardiovascular diseases, and neurodegenerative disorders, making it a significant target for drug development. Research on PTGS2 recombinant proteins has advanced significantly, as these proteins can be produced in vitro for various applications, including structural studies, drug screening, and the development of inhibitors. The production of recombinant PTGS2 allows for the study of its catalytic mechanisms, regulation, and interaction with various substrates and inhibitors. Moreover, understanding the structure and function of PTGS2 contributes to the development of specific COX-2 inhibitors, which are crucial for therapeutic interventions in inflammatory diseases and certain cancer types. The potential for PTGS2 as a biomarker for disease progression continues to be explored, highlighting its relevance in both basic and clinical research. As researchers delve deeper into the functional aspects of PTGS2, the insights gained from studies on its recombinant protein can pave the way for innovative therapeutic strategies and improved patient outcomes.
